Skip to main content
SpringerLink
Log in

[68Ga]-DOTATATE PET in the Central Nervous System

  • Chapter
  • First Online:
Hybrid PET/MR Neuroimaging

  • 1795 Accesses

Abstract

Gallium-68 ([68Ga])-DOTATATE is a radiotracer that targets somatostatin receptors (SSTRs) with a high specificity for SSTR subtype 2, the receptor most commonly found on neuroendocrine cells. A number of tumors involving the central nervous system (CNS) demonstrate SSTR expression on their cell surface, which can serve as a target for molecular imaging with SSTR-ligand receptors. This chapter will focus on the use of [68Ga]-DOTATATE PET for CNS tumors, including meningioma, paraganglioma, esthesioneuroblastoma, hemangioblastoma, medulloblastoma, and pituitary adenomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57(6):872–8.

    Article  CAS  Google Scholar 

  2. Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ, Osborne JR, et al. Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging [Internet]. 2019;56:146–54. https://browzine.com/articles/298780256

    Article  Google Scholar 

  3. Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57(12):1949–56.

    Article  CAS  Google Scholar 

  4. Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging [Internet]. 2013;40(11):1770–80. https://browzine.com/articles/47465271

    Article  CAS  Google Scholar 

  5. Hofman MS, Eddie Lau WF, Hicks RJ. Somatostatin receptor imaging with 68 Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radioraphics. 2016;35(2):500–16.

    Article  Google Scholar 

  6. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, Reubi JCBJ. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31(12):1025–32.

    Article  Google Scholar 

  7. Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66(January):18–22.

    Article  Google Scholar 

  8. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology. 2017;19(5):v1–88.

    Article  Google Scholar 

  9. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol [Internet]. 2009;95(3):367–75. https://browzine.com/articles/39344544

    Article  Google Scholar 

  10. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4–23.

    Article  Google Scholar 

  11. Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58(10):1580–7.

    Article  CAS  Google Scholar 

  12. Chidambaram S, Pannullo SC, Roytman M, Pisapia DJ, Liechty B, Magge RS, et al. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Neurosurg Focus. 2019;46(6):E10.

    Article  Google Scholar 

  13. Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging. 2019;29:650.

    Article  Google Scholar 

  14. Rao AB, Koeller KK. 1 From the Departments of Radiologic Pathology. Vol. 19, Uniformed Services University of the Health Sciences. 1999.

    Google Scholar 

  15. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer [Internet]. 2014;14(2):108–19. https://browzine.com/articles/49002866

    Article  CAS  Google Scholar 

  16. Roytman M, Lin E, Phillips CD, Ivanidze J. Head and neck paragangliomas: CT, MR, and 68Ga-DOTATATE PET imaging. Neurographics. 2020;10(1):8–18.

    Article  Google Scholar 

  17. Pillai S, Gopalan V, Smith RA, Lam AK-Y. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol [Internet]. 2016;100:190–208. https://browzine.com/articles/57826827

    Article  Google Scholar 

  18. Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol. 2013;20(5):1444–50.

    Article  Google Scholar 

  19. Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck Paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med [Internet]. 2016;57(2):186–91. https://browzine.com/articles/56945697

    Article  CAS  Google Scholar 

  20. Abdelmeguid AS. Olfactory neuroblastoma. Curr Oncol Rep. 2018;20(7):7.

    Article  Google Scholar 

  21. Bell D. Sinonasal neuroendocrine neoplasms: current challenges and advances in diagnosis and treatment, with a focus on olfactory neuroblastoma. Head Neck Pathol [Internet]. 2018;12(1):22–30. https://doi.org/10.1007/s12105-018-0887-5.

    Article  Google Scholar 

  22. Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: results and outcomes of a single institution’s experience. Skull Base. 2009;19(2):133–40.

    Article  Google Scholar 

  23. Chung YS, Na M, Ku CR, Kim SH, Kim EH. Adrenocorticotropic hormone-secreting esthesioneuroblastoma with ectopic cushing’s syndrome. Yonsei Med J. 2020;61(3):257–61.

    Article  Google Scholar 

  24. Banuchi VE, Dooley L, Lee NY, Pfister DG, McBride S, Riaz N, et al. Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope. 2016;126(7):1556–61.

    Article  Google Scholar 

  25. Kadish S, Goodman M, Wang C. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37(3):1571–6.

    Article  CAS  Google Scholar 

  26. Joshi RR, Husain Q, Roman BR, Cracchiolo J, Yu Y, Tsai J, Kang J, McBride S, Lee NY, Morris L, Ganly I, Tabar V, Cohen M. Comparing Kadish, TNM, and the modified Dulguerov staging systems for Esthesioneuroblastoma. J Surg Oncol. 2019;119(1):130–42.

    Article  Google Scholar 

  27. Hyams V, Batsakis J ML. Tumors of the upper respiratory tract and ear. Armed forces institute of pathology fascicles, 2nd series. Washingt Am Regist Pathol Press. 1988.

    Google Scholar 

  28. Bell D, Saade R, Roberts D, Ow TJ, Kupferman M, DeMonte F, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for Esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51–9.

    Article  Google Scholar 

  29. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2(11):683–90.

    Article  CAS  Google Scholar 

  30. Mills SA, Oh MC, Rutkowski MJ, Sughrue ME, Barani IJ, Parsa AT. Supratentorial hemangioblastoma: clinical features, prognosis, and predictive value of location for von HippelLindau disease. Neuro-Oncology. 2012;14(8):1097–104.

    Article  Google Scholar 

  31. Hussein MR. Central nervous system capillary haemangioblastoma: the pathologist’s viewpoint. Int J Exp Pathol. 2007;88(5):311–24.

    Article  CAS  Google Scholar 

  32. Abhik RC, Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, et al. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep [Internet]. 2017;7(September 2016):1–9. https://doi.org/10.1038/srep40822.

    Article  CAS  Google Scholar 

  33. Papadakis GZ, Millo C, Jassel IS, Bagci U, Sadowski SM, Karantanas AH, et al. 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau disease-associated retinal Hemangioblastoma. Clin Nucl Med. 2017;42(3):189–90.

    Article  Google Scholar 

  34. Sharma P, Dhull VS, Bal C, Malhotra A, Kumar R. Von Hippel-Lindau syndrome: demonstration of entire disease spectrum with 68Ga-DOTANOC PET-CT. Korean J Radiol. 2014;15(1):169–72.

    Article  Google Scholar 

  35. Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, et al. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst. 2013;29(8):1253–62.

    Article  Google Scholar 

  36. Chan M, Hsiao E. Incidental finding of cerebellar medulloblastoma on 68Ga-DOTATATE PET/CT in a patient with appendiceal carcinoid. Clin Nucl Med. 2016;41(11):886–7.

    Article  Google Scholar 

  37. Faltermeier CM, Magill ST, Blevins LS, Aghi MK. Molecular biology of pituitary adenomas. Neurosurg Clin N Am [Internet]. 2019;30(4):391–400. https://doi.org/10.1016/j.nec.2019.05.001.

    Article  Google Scholar 

  38. Papadakis GZ, Bagci U, Sadowski SM, Patronas NJ, Stratakis CA. Ectopic ACTH and CRH co-secreting tumor localized by 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2015;40(7):576–8.

    Article  Google Scholar 

  39. Wang H, Hou B, Lu L, Feng M, Zang J, Yao S, et al. PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med. 2018;59(3):523–8.

    Article  CAS  Google Scholar 

  40. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50(12):1927–32.

    Article  Google Scholar 

  41. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30(4):281–6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Michelle Roytman

  2. Department of Diagnostic Radiology, Division of Molecular Imaging and Therapeutics, Division of Neuroradiology, Molecular Imaging Innovations Institute, Weill Cornell Medicine, Department of Radiology, New York, NY, USA

    Jana Ivanidze

Authors
  1. Michelle Roytman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jana Ivanidze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jana Ivanidze .

Editor information

Editors and Affiliations

  1. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research, Manhasset, NY, USA

    Ana M. Franceschi

  2. Stony Brook University Hospital, Stony Brook, NY, USA

    Dinko Franceschi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roytman, M., Ivanidze, J. (2022). [68Ga]-DOTATATE PET in the Central Nervous System. In: Franceschi, A.M., Franceschi, D. (eds) Hybrid PET/MR Neuroimaging. Springer, Cham. https://doi.org/10.1007/978-3-030-82367-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82367-2_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82366-5

  • Online ISBN: 978-3-030-82367-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation